NCNA
Price
$1.28
Change
-$0.06 (-4.48%)
Updated
Jul 13 closing price
Capitalization
5.24M
30 days until earnings call
Intraday BUY SELL Signals
PALI
Price
$1.89
Change
-$0.07 (-3.57%)
Updated
Jul 13 closing price
Capitalization
328.44M
43 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NCNA vs PALI

NCNA vs PALI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
NCNA vs. PALI commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NCNA is a Hold and PALI is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (NCNA: $1.28 vs. PALI: $1.96)
Brand notoriety: NCNA and PALI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NCNA: 55% vs. PALI: 62%
Market capitalization -- NCNA: $5.24M vs. PALI: $328.44M
NCNA [@Biotechnology] is valued at $5.24M. PALI’s [@Biotechnology] market capitalization is $328.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $121.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NCNA’s FA Score shows that 1 FA rating(s) are green whilePALI’s FA Score has 0 green FA rating(s).

  • NCNA’s FA Score: 1 green, 4 red.
  • PALI’s FA Score: 0 green, 5 red.
According to our system of comparison, both NCNA and PALI are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NCNA’s TA Score shows that 4 TA indicator(s) are bullish while PALI’s TA Score has 5 bullish TA indicator(s).

  • NCNA’s TA Score: 4 bullish, 6 bearish.
  • PALI’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, PALI is a better buy in the short-term than NCNA.

Price Growth

NCNA (@Biotechnology) experienced а -7.91% price change this week, while PALI (@Biotechnology) price change was -6.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.21%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1806.27%.

Reported Earning Dates

NCNA is expected to report earnings on Aug 13, 2026.

PALI is expected to report earnings on Aug 25, 2026.

Industries' Descriptions

@Biotechnology (-3.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PALI($328M) has a higher market cap than NCNA($5.24M). PALI has higher P/E ratio than NCNA: PALI (15.75) vs NCNA (0.01). PALI YTD gains are higher at: -19.574 vs. NCNA (-64.444). NCNA has higher annual earnings (EBITDA): -22.55M vs. PALI (-24.14M). PALI has more cash in the bank: 133M vs. NCNA (21.5M). PALI has less debt than NCNA: PALI (211K) vs NCNA (680K). NCNA (0) and PALI (0) have equivalent revenues.
NCNAPALINCNA / PALI
Capitalization5.24M328M2%
EBITDA-22.55M-24.14M93%
Gain YTD-64.444-19.574329%
P/E Ratio0.0115.750%
Revenue00-
Total Cash21.5M133M16%
Total Debt680K211K322%
FUNDAMENTALS RATINGS
NCNA vs PALI: Fundamental Ratings
NCNA
PALI
OUTLOOK RATING
1..100
5350
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9239
P/E GROWTH RATING
1..100
3745
SEASONALITY SCORE
1..100
5047

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NCNA's Valuation (5) in the Biotechnology industry is somewhat better than the same rating for PALI (70) in the null industry. This means that NCNA’s stock grew somewhat faster than PALI’s over the last 12 months.

NCNA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PALI (100) in the null industry. This means that NCNA’s stock grew similarly to PALI’s over the last 12 months.

PALI's SMR Rating (98) in the null industry is in the same range as NCNA (100) in the Biotechnology industry. This means that PALI’s stock grew similarly to NCNA’s over the last 12 months.

PALI's Price Growth Rating (39) in the null industry is somewhat better than the same rating for NCNA (92) in the Biotechnology industry. This means that PALI’s stock grew somewhat faster than NCNA’s over the last 12 months.

NCNA's P/E Growth Rating (37) in the Biotechnology industry is in the same range as PALI (45) in the null industry. This means that NCNA’s stock grew similarly to PALI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NCNAPALI
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
N/A
Stochastic
ODDS (%)
Bullish Trend 6 days ago
86%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 4 days ago
86%
MACD
ODDS (%)
Bearish Trend 6 days ago
90%
Bullish Trend 4 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 4 days ago
78%
Advances
ODDS (%)
Bullish Trend 26 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 4 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
NCNA
Daily Signal:
Gain/Loss:
PALI
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GGOTX15.05N/A
N/A
Goldman Sachs Mid Cap Growth Inv
JSEZX33.70N/A
N/A
JPMorgan Small Cap Equity R2
ECFVX23.40N/A
N/A
Eaton Vance Focused Value Opps C
SUSSX17.33N/A
N/A
State Street Instl US Equity Svc
LGRNX32.16-0.29
-0.89%
Loomis Sayles Growth N

PALI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PALI has been closely correlated with RNAC. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if PALI jumps, then RNAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PALI
1D Price
Change %
PALI100%
-3.57%
RNAC - PALI
81%
Closely correlated
-8.77%
AGEN - PALI
81%
Closely correlated
+82.69%
NCNA - PALI
81%
Closely correlated
-4.48%
TAOX - PALI
81%
Closely correlated
-2.90%
NRXP - PALI
74%
Closely correlated
-0.95%
More